{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:02:46Z","timestamp":1792267366713,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1053\/j.gastro.2021.07.025","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T10:13:39Z","timestamp":1627035219000},"page":"1475-1486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":219,"title":["TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial"],"prefix":"10.1053","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwana","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Jean","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeral","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Wayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"O\u2019Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Grimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wai-Sun Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kemble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.07.025_bib1","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","author":"Simon","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.025_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.025_bib3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.07.025_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2021.07.025_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.aax6594","article-title":"Lowering ceramides to overcome diabetes","volume":"365","author":"Kusminski","year":"2019","journal-title":"Science"},{"key":"10.1053\/j.gastro.2021.07.025_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.07.025_bib7","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2021.07.025_bib8","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1038\/s41598-018-29735-6","article-title":"Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin","volume":"8","author":"Ogawa","year":"2018","journal-title":"Sci Rep-uk"},{"key":"10.1053\/j.gastro.2021.07.025_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.21037\/atm.2020.02.21","article-title":"Palmitic acid stimulates NLRP3 inflammasome activation through TLR4-NF-\u03baB signal pathway in hepatic stellate cells","volume":"8","author":"Dong","year":"2020","journal-title":"Ann Transl Medicine"},{"key":"10.1053\/j.gastro.2021.07.025_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jnutbio.2016.01.010","article-title":"Docosahexaenoic acid and palmitic acid reciprocally modulate monocyte activation in part through endoplasmic reticulum stress","volume":"32","author":"Snodgrass","year":"2016","journal-title":"J\u00a0Nutritional Biochem"},{"key":"10.1053\/j.gastro.2021.07.025_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-511X-12-98","article-title":"Role of ceramide in diabetes mellitus: evidence and mechanisms","volume":"12","author":"Galadari","year":"2013","journal-title":"Lipids Health Dis"},{"key":"10.1053\/j.gastro.2021.07.025_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tem.2012.04.005","article-title":"Role of ceramides in nonalcoholic fatty liver disease","volume":"23","author":"Pagadala","year":"2012","journal-title":"Trends Endocrinol Metabolism"},{"key":"10.1053\/j.gastro.2021.07.025_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nm0410-400","article-title":"Diacylglycerol-mediated insulin resistance","volume":"16","author":"Erion","year":"2010","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2021.07.025_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","article-title":"\u201cNew\u201d hepatic fat activates PPAR\u03b1 to maintain glucose, lipid, and cholesterol homeostasis","volume":"1","author":"Chakravarthy","year":"2005","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2021.07.025_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature20117","article-title":"Fatty acid synthesis configures the plasma membrane for inflammation in diabetes","volume":"539","author":"Wei","year":"2016","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.07.025_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","author":"Bates","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1053\/j.gastro.2021.07.025_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31000","article-title":"First-in-class fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.07.025_bib18","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.025_bib19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J\u00a0Proteome Res"},{"key":"10.1053\/j.gastro.2021.07.025_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.07.025_bib21","unstructured":"Stine JG, Munaganuru N, Barnard A, et\u00a0al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis [published online ahead of print August 21, 2020]. Clin Gastroenterol Hepatol 10.1016\/j.cgh.2020.08.061"},{"key":"10.1053\/j.gastro.2021.07.025_bib22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MR-PDFF and histologic response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.07.025_bib23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.31624","article-title":"MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.07.025_bib24","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/S0022-2275(20)32553-0","article-title":"Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men","volume":"39","author":"Aarsland","year":"1998","journal-title":"J\u00a0Lipid Res"},{"key":"10.1053\/j.gastro.2021.07.025_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.025_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.07.025_bib27","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","author":"Tamaki","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.025_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30656-5","article-title":"Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy; a secondary analysis of the resmetirom randomized placebo controlled Phase 2 clinical trial","volume":"73","author":"Loomba","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.07.025_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2021.07.025_bib30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2021.07.025_bib31","doi-asserted-by":"crossref","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1053\/j.gastro.2021.07.025_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-15-A54","article-title":"Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination\u2013final results of dose escalation","volume":"14","author":"Brenner","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2021.07.025_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"Eclinicalmedicine"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521032765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521032765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:49:51Z","timestamp":1762163391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521032765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0016508521032765"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.07.025","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}